Eichenfield, Lawrence F. http://orcid.org/0000-0002-2760-0474
Stein Gold, Linda F.
Lynde, Charles
Guenther, Lyn
Greenberger, Shoshana
Chu, Chia-Yu
Ghodsi, Zara
Vlahos, Bonnie
Sanders, Paul
Cha, Amy
Canosa, Juliana M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01129-9
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 14 December 2023
Accepted: 22 February 2024
First Online: 28 March 2024
Declarations
:
: Lawrence F. Eichenfield has served as a scientific advisor, consultant, and/or clinical trial investigator for Pfizer Inc., AbbVie, Amgen, Aslan Pharmaceuticals, Castle Biosciences, Dermavant, Eli Lilly and Company, Forté, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Regeneron Pharmaceuticals, and Sanofi-Genzyme. Linda F. Stein-Gold has received grants from Pfizer Inc., Incyte, and LEO Pharma and has received payment for lectures from Pfizer Inc. and LEO Pharma. Charles Lynde has been a speaker, consultant, and/or principal investigator for Pfizer Inc., AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Eli Lilly and Company, Fresnius Kabi, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche-Posay, LEO Pharma, L’Oreal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Regeneron, Roche, Sanofi-Genzyme, Sandoz, Sentrex, SunPharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health, and has served as a principal investigator for Acelyrin, Akros, Altius, Avillion, Celltrion, Concert, Devonian, Evelo, and MoonLake. Lyn Guenther has received consulting fees/honoraria from Pfizer Inc., Aralez, Bausch Health, BMS, Cipher, Eli Lilly and Company, GSK, Incyte, Janssen, Johnson and Johnson, La Roche-Posay, LEO Pharma, Merck, Miravo, Novartis, and UCB; has been a member of a Speaker’s Bureau/advisory board member for Pfizer Inc., Abbvie, Actilion, Amgen, Altana, Aralez, Aslan, Bausch Health, Eli Lilly and Company, Galderma, Janssen, Johnson and Johnson, La Roche-Posay, LEO Pharma, Novartis, and Sanofi Aventis, UCB; and has received research grants from Pfizer Inc., Abbvie, Actilion, Amgen, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Cipher, Eli Lilly and Company, Galderma, Innovaderm, Janssen, La Roche-Posay, LEO Pharma, Merck, Novartis, and UCB. Shoshana Greenberger served as an investigator for Pfizer Inc., AbbVie, Amgen, Eli Lilly and Company, and, Novartis; has served on a Speaker’s Bureau/advisory board for Pfizer Inc., AbbVie, Sanofi, Pfizer, Padagis, and Dexcel Pharma; has provided investigator services for Pfizer Inc., AbbVie, Amgen, and Eli Lilly and Company; and has received research grants from Pfizer. Chia-Yu Chu has served as an investigator for Pfizer Inc., AbbVie, Amgen, Dermira, Eli Lilly and Company, Janssen, Novartis, Oneness Biotech, Regeneron, Roche, and Sanofi; has served as a consultant for Pfizer Inc., AbbVie, Eli Lilly and Company, Janssen, Novartis, Roche, and Sanofi; has served as a speaker for Pfizer Inc., AbbVie, Eli Lilly and Company, Janssen, Mylan, Novartis, Roche, Sanofi, and Viatris; and has served on the advisory boards of Pfizer Inc., AbbVie, Amgen, Eli Lilly and Company, Janssen, Mylan, Roche, Sanofi, and Viatris. Bonnie Vlahos, Paul Sanders, Amy Cha, Juliana M. Canosa, and Zara Ghodsi are employees and shareholders of Pfizer Inc.
: This planned exploratory analysis of data from the CrisADe CONTROL study was exempt from institutional review board approval. All participants or parents/guardians provided written informed consent for participation in the CrisADe CONTROL study. The CrisADe CONTROL study was approved by the Quorum Review Institutional Review Board and was conducted in accordance with the ethical principles originating in the Declaration of Helsinki.